PRC
AXSM icon

Pearl River Capital’s Axsome Therapeutics AXSM Stock Holding History

Pearl River Capital’s Portfolio AXSM Stock Details AXSM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-5,806
Closed -$462K – 472
2023
Q4 		$462K Sell
5,806
-4,129
-42% -$276K 0.07% 330
2023
Q3 		$694K Sell
9,935
-6,453
-39% -$482K 0.11% 272
2023
Q2 		$1.18M Buy
16,388
+6,766
+70% +$499K 0.19% 170
2023
Q1 		$593K Buy
9,622
+1,960
+26% +$129K 0.09% 289
2022
Q4 		$591K Buy
+7,662
New +$458K 0.1% 294
2020
Q2 		– Sell
-3,473
Closed -$204K – 302
2020
Q1 		$204K Buy
+3,473
New +$283K 0.39% 79

Other funds holding AXSM

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Pearl River Capital's AXSM Position: Q1 2024 in Review

Pearl River Capital sold out of Axsome Therapeutics (AXSM) in Q1 2024, closing a stake of 5,806 shares — an estimated $462K sold.

Pearl River Capital first reported a position in AXSM in Q1 2020 and held it in 6 quarters. The position peaked at $1.18M in Q2 2023. 260 funds tracked by Wall St. Rank hold AXSM as of Q1 2024.

  • Pearl River Capital reported no remaining Axsome Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Pearl River Capital sold 5,806 Axsome Therapeutics shares in Q1 2024, an estimated $462K.
  • Pearl River Capital first reported a position in Axsome Therapeutics in Q1 2020 and held it in 6 quarters.
  • Pearl River Capital's Axsome Therapeutics position peaked at $1.18M in Q2 2023.
  • 260 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q1 2024.

Based on Pearl River Capital's 13F filing for Q1 2024, filed 14 May 2024.